Free Trial
Final Hours! Save $100 on MarketBeat All Access Before 11:59 PM
  • 0Days
  • 0Hours
  • 0Minutes
  • 0Seconds
Lock In $149 Tonight
Claim MarketBeat All Access Sale Promotion

Xenon Pharmaceuticals (XENE) Financials

Xenon Pharmaceuticals logo
$54.17 0.00 (0.00%)
Closing price 05/22/2026 04:00 PM Eastern
Extended Trading
$54.14 -0.03 (-0.06%)
As of 05/22/2026 05:36 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Xenon Pharmaceuticals

Annual Income Statements for Xenon Pharmaceuticals

This table shows Xenon Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -16 -23 -31 -32 -40 -28 -77 -125 0.00 -236 -344
Consolidated Net Income / (Loss)		 -16 -23 -31 -34 -42 -29 -79 -125 -182 -234 -346
Net Income / (Loss) Continuing Operations		 -16 -23 -31 -34 -42 -29 -79 -125 -182 -234 -346
Total Pre-Tax Income 		-16 -23 -32 -35 -42 -29 -79 -125 -183 -238 -345
Total Operating Income		 -9.36 -25 -33 -38 -43 -31 -79 -129 -214 -279 -373
Total Gross Profit		 16 1.80 0.31 -6.00 6.83 32 18 9.43 0.00 0.00 7.50
Total Revenue		 16 1.80 0.31 0.00 6.83 32 18 9.43 0.00 0.00 7.50
Operating Revenue		 16 1.80 0.31 - 6.83 32 18 9.43 0.00 0.00 7.50
Total Cost of Revenue		 0.00 0.00 0.00 6.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 25 27 33 32 50 63 97 139 214 279 381
Selling, General & Admin Expense		 9.79 6.79 7.31 8.41 11 13 22 33 47 69 80
Research & Development Expense		 15 20 26 24 39 51 75 106 168 210 301
Total Other Income / (Expense), net		 -6.39 1.82 0.48 3.52 1.20 2.20 0.11 3.89 31 41 28
Interest & Investment Income		 0.54 0.50 0.48 1.22 2.35 2.28 0.47 8.71 28 42 27
Other Income / (Expense), net		 -6.93 1.32 0.00 3.70 0.28 1.40 -0.36 -4.83 3.75 -1.06 1.35
Income Tax Expense		 - - - -0.02 -0.02 -0.26 -0.01 0.12 -0.29 -4.09 1.02
Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders)		 - - - - - - - - - 1.54 -1.95
Basic Earnings per Share		 ($1.10) ($1.48) ($1.71) ($1.63) ($1.54) ($0.81) ($1.77) ($2.06) ($2.73) ($3.01) ($4.36)
Weighted Average Basic Shares Outstanding		 14.28M 15.49M 17.99M 19.43M 25.94M 34.54M 43.63M 60.54M 66.89M 77.89M 79.25M
Diluted Earnings per Share		 ($1.10) ($1.48) ($1.72) ($1.63) ($1.54) ($0.81) ($1.77) ($2.06) ($2.73) ($3.01) ($4.36)
Weighted Average Diluted Shares Outstanding		 14.28M 15.49M 18.00M 19.43M 25.94M 34.54M 43.63M 60.54M 66.89M 77.89M 79.25M
Weighted Average Basic & Diluted Shares Outstanding		 14.30M 17.94M 18.00M 19.43M 25.94M 34.54M 43.63M 63.04M 75.43M 76.54M 83.19M

Quarterly Income Statements for Xenon Pharmaceuticals

This table shows Xenon Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -48 -44 -50 -58 -59 -69 -64 -84 -91 -105 -104
Consolidated Net Income / (Loss)		 -48 -45 -48 -58 -63 -66 -65 -85 -91 -105 -102
Net Income / (Loss) Continuing Operations		 -48 -45 -48 -58 -63 -66 -65 -85 -91 -105 -102
Total Pre-Tax Income 		-49 -45 -48 -58 -63 -70 -65 -85 -90 -105 -105
Total Operating Income		 -56 -54 -59 -69 -74 -77 -73 -94 -96 -110 -112
Total Gross Profit		 0.00 - 0.00 0.00 0.00 - 7.50 0.00 0.00 - 0.00
Total Revenue		 0.00 - 0.00 0.00 0.00 - 7.50 0.00 0.00 - 0.00
Operating Revenue		 - - 0.00 0.00 0.00 - 7.50 0.00 0.00 - 0.00
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 56 54 59 69 74 77 80 94 96 110 112
Selling, General & Admin Expense		 13 13 15 19 17 18 19 19 19 22 24
Research & Development Expense		 43 41 44 50 57 59 61 75 77 88 89
Total Other Income / (Expense), net		 7.07 8.75 12 11 11 7.94 8.12 8.90 6.12 5.04 7.46
Interest & Investment Income		 6.98 8.69 11 11 10 9.42 8.08 7.20 6.21 5.34 6.91
Other Income / (Expense), net		 0.08 0.06 0.17 0.01 0.24 -1.48 0.04 1.70 -0.09 -0.30 0.55
Income Tax Expense		 -0.16 -0.21 0.41 -0.33 -0.32 -3.85 0.43 -0.63 0.68 0.54 -2.57
Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders)		 - - 1.69 0.44 -3.55 - -0.78 -0.95 -0.36 0.14 1.55
Basic Earnings per Share		 ($0.73) ($0.65) ($0.62) ($0.75) ($0.81) ($0.83) ($0.83) ($1.07) ($1.15) ($1.31) ($1.17)
Weighted Average Basic Shares Outstanding		 66.00M 66.89M 77.59M 77.67M 77.93M 77.89M 78.69M 78.95M 79.25M 79.25M 87.35M
Diluted Earnings per Share		 ($0.73) ($0.65) ($0.62) ($0.75) ($0.81) ($0.83) ($0.83) ($1.07) ($1.15) ($1.31) ($1.17)
Weighted Average Diluted Shares Outstanding		 66.00M 66.89M 77.59M 77.67M 77.93M 77.89M 78.69M 78.95M 79.25M 79.25M 87.35M
Weighted Average Basic & Diluted Shares Outstanding		 65.43M 75.43M 75.47M 75.76M 76.24M 76.54M 76.73M 77.11M 77.28M 83.19M 96.67M

Annual Cash Flow Statements for Xenon Pharmaceuticals

This table details how cash moves in and out of Xenon Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 -13 -42 3.39 48 -43 20 131 -118 91 -5.93 56
Net Cash From Operating Activities		 -18 -20 -29 -35 -4.71 -48 -70 -101 -151 -181 -279
Net Cash From Continuing Operating Activities		 -18 -20 -29 -35 -4.71 -48 -70 -101 -151 -181 -279
Net Income / (Loss) Continuing Operations		 -16 -23 -31 -34 -42 -29 -79 -125 -182 -234 -346
Consolidated Net Income / (Loss)		 -16 -23 -31 -34 -42 -29 -79 -125 -182 -234 -346
Depreciation Expense		 1.04 0.86 0.65 0.59 0.43 0.64 0.91 1.41 2.06 2.56 2.54
Non-Cash Adjustments To Reconcile Net Income		 11 0.86 0.76 -1.13 2.54 6.23 11 23 24 54 62
Changes in Operating Assets and Liabilities, net		 -14 1.71 0.56 0.03 33 -26 -2.59 -1.28 5.34 -3.15 2.46
Net Cash From Investing Activities		 10 -48 24 -29 -66 -17 -247 -293 -111 165 218
Net Cash From Continuing Investing Activities		 10 -48 24 -29 -66 -17 -247 -293 -111 165 218
Purchase of Property, Plant & Equipment		 -0.55 -0.28 -0.32 -0.51 -1.24 -2.64 -2.05 -2.89 -5.62 -3.08 -0.80
Purchase of Investments		 0.00 -48 -28 -77 -140 -229 -389 -551 -794 -532 -356
Sale and/or Maturity of Investments		 11 0.00 53 49 76 215 145 261 688 700 574
Net Cash From Financing Activities		 0.28 24 7.07 112 28 86 448 278 354 12 117
Net Cash From Continuing Financing Activities		 0.28 24 7.07 112 28 86 448 278 354 12 117
Issuance of Common Equity		 0.28 24 0.18 103 28 103 448 278 0.00 12 0.00
Other Financing Activities, net		 - - - - - - - 0.71 354 0.05 117
Effect of Exchange Rate Changes		 -5.74 1.89 0.75 - 0.41 -0.59 -0.59 -2.48 0.38 -1.67 0.46

Quarterly Cash Flow Statements for Xenon Pharmaceuticals

This table details how cash moves in and out of Xenon Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 35 49 -90 78 -49 55 -26 19 -31 95 347
Net Cash From Operating Activities		 -48 -35 -46 -33 -51 -54 -62 -64 -72 -81 -89
Net Cash From Continuing Operating Activities		 -48 -35 -46 -33 -52 -54 -62 -64 -72 -81 -89
Net Income / (Loss) Continuing Operations		 -48 -45 -48 -58 -63 -66 -65 -85 -91 -105 -102
Consolidated Net Income / (Loss)		 -48 -45 -48 -58 -63 -66 -65 -85 -91 -105 -102
Depreciation Expense		 1.73 -0.63 0.59 0.66 0.67 0.63 0.66 0.63 0.64 0.61 0.59
Non-Cash Adjustments To Reconcile Net Income		 7.95 4.58 6.70 15 12 6.54 16 17 14 15 16
Changes in Operating Assets and Liabilities, net		 -3.45 -0.46 -5.55 9.76 -1.23 2.44 -13 2.77 4.60 8.19 -2.93
Net Cash From Investing Activities		 54 -240 -43 111 1.98 99 35 82 39 63 -407
Net Cash From Continuing Investing Activities		 54 -240 -43 111 1.98 99 35 82 39 63 -407
Purchase of Property, Plant & Equipment		 -1.20 -0.08 -0.19 -1.51 -0.59 -0.78 -0.04 -0.16 -0.28 -0.32 -0.13
Purchase of Investments		 -147 -377 -177 -125 -164 -66 -131 -89 -75 -61 -506
Sale and/or Maturity of Investments		 202 137 134 237 167 166 166 171 114 124 99
Net Cash From Financing Activities		 30 324 0.00 - - 12 1.15 0.07 2.36 114 843
Net Cash From Continuing Financing Activities		 30 324 0.00 - - 12 1.15 0.07 2.36 114 843
Issuance of Common Equity		 - 324 0.00 - - 12 0.00 - - - 838
Other Financing Activities, net		 - - 0.00 - - - 1.15 0.07 2.36 114 5.49
Effect of Exchange Rate Changes		 -0.29 0.25 -0.37 -0.20 - - -0.06 0.63 -0.01 -0.10 -0.13
Cash Interest Received		 - - 0.00 - - - 0.00 - - - 0.00
Cash Income Taxes Paid		 - - - - - - 0.00 - 1.65 - 0.00

Annual Balance Sheets for Xenon Pharmaceuticals

This table presents Xenon Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 64 67 46 122 148 189 572 754 965 798 633
Total Current Assets		 61 66 45 121 145 182 559 600 645 635 561
Cash & Equivalents		 59 17 20 68 25 45 176 57 149 143 199
Short-Term Investments		 0.00 47 23 52 117 132 376 535 489 484 350
Accounts Receivable		 0.32 0.20 0.44 0.15 0.81 1.82 2.77 0.99 0.87 1.47 1.37
Prepaid Expenses		 1.90 1.33 0.72 1.88 2.70 2.96 4.48 7.23 6.01 6.89 10
Plant, Property, & Equipment, net		 1.99 1.40 1.07 0.99 1.66 3.55 4.47 6.50 9.65 10 8.72
Total Noncurrent Assets		 1.09 0.41 0.23 0.11 1.17 3.85 8.52 147 310 153 64
Long-Term Investments		 - - - - - - 0.00 129 293 127 37
Noncurrent Deferred & Refundable Income Taxes		 - - - 0.11 0.24 0.52 0.47 0.51 0.80 9.67 13
Other Noncurrent Operating Assets		 1.09 0.41 0.23 - 0.93 3.33 8.06 18 17 15 14
Total Liabilities & Shareholders' Equity		 64 67 46 122 148 189 572 754 965 798 633
Total Liabilities		 2.92 3.59 10 19 56 18 22 33 37 43 51
Total Current Liabilities		 2.78 3.59 4.08 4.12 43 15 14 23 27 36 42
Accounts Payable		 2.63 3.59 3.38 4.12 8.82 11 14 22 26 34 40
Other Current Liabilities		 - - - - 0.17 0.27 0.61 0.49 1.30 1.37 1.53
Total Noncurrent Liabilities		 0.13 0.00 6.10 15 12 3.05 7.65 9.95 9.60 7.65 9.61
Other Noncurrent Operating Liabilities		 0.13 - - - 0.74 3.05 7.65 9.95 9.60 7.65 9.61
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 61 64 36 103 92 171 550 721 928 755 582
Total Preferred & Common Equity		 61 64 36 103 92 171 550 721 928 755 582
Total Common Equity		 61 64 36 96 84 164 542 721 928 755 582
Common Stock		 182 208 210 304 335 443 901 1,207 1,593 1,656 1,827
Retained Earnings		 -120 -143 -173 -208 -250 -278 -357 -483 -665 -899 -1,245
Accumulated Other Comprehensive Income / (Loss)		 -0.99 -0.99 -0.99 -0.99 -0.99 -0.99 -0.99 -3.00 -0.08 -1.61 0.34

Quarterly Balance Sheets for Xenon Pharmaceuticals

This table presents Xenon Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 776 720 685 671 919 884 836 743 674 608 1,387
Total Current Assets		 649 533 545 531 707 728 660 566 500 480 1,107
Cash & Equivalents		 103 70 65 100 59 137 88 117 135 105 546
Short-Term Investments		 535 458 475 427 641 585 566 433 352 358 549
Accounts Receivable		 2.48 2.22 2.12 0.81 0.83 0.85 0.94 8.65 1.10 0.81 1.17
Prepaid Expenses		 8.51 4.09 2.89 3.53 6.77 5.70 4.69 7.26 12 17 11
Plant, Property, & Equipment, net		 4.58 7.98 9.56 10 9.39 10 10 9.70 9.21 8.89 8.29
Total Noncurrent Assets		 122 179 131 130 202 146 166 168 165 119 272
Long-Term Investments		 114 160 113 112 186 129 149 141 137 93 245
Noncurrent Deferred & Refundable Income Taxes		 0.51 0.22 0.45 0.60 0.40 0.73 1.05 11 11 12 12
Other Noncurrent Operating Assets		 7.56 18 18 17 16 16 16 16 16 14 15
Total Liabilities & Shareholders' Equity		 776 720 685 671 919 884 836 743 674 608 1,387
Total Liabilities		 23 33 38 35 31 40 38 39 40 48 49
Total Current Liabilities		 16 22 28 25 22 31 30 32 33 38 40
Accounts Payable		 16 21 27 23 21 30 28 31 32 37 38
Other Current Liabilities		 0.00 1.19 1.22 1.25 1.32 1.35 1.39 1.38 1.46 1.50 1.56
Total Noncurrent Liabilities		 7.16 10 10 9.76 9.10 8.68 8.40 7.29 7.26 9.99 9.18
Other Noncurrent Operating Liabilities		 7.16 10 10 9.76 9.10 8.68 8.40 7.29 7.26 9.99 9.18
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 753 687 646 637 888 844 798 704 634 560 1,338
Total Preferred & Common Equity		 753 687 646 637 888 844 798 704 634 560 1,338
Total Common Equity		 753 687 646 637 888 844 798 704 634 560 1,338
Common Stock		 1,201 1,213 1,222 1,260 1,603 1,617 1,630 1,669 1,683 1,699 2,687
Retained Earnings		 -445 -524 -572 -620 -713 -771 -834 -965 -1,049 -1,140 -1,348
Accumulated Other Comprehensive Income / (Loss)		 -2.96 -1.82 -3.30 -2.95 -1.77 -2.21 1.34 -0.84 0.11 0.48 -1.21

Annual Metrics And Ratios for Xenon Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Xenon Pharmaceuticals' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 -45.09% -88.43% -82.75% -100.00% 0.00% 371.02% -42.68% -48.83% -100.00% 0.00% 0.00%
EBITDA Growth		 -215.68% -48.38% -40.99% -4.88% -24.23% 30.15% -170.09% -67.94% -58.07% -32.80% -32.89%
EBIT Growth		 -230.88% -44.23% -38.61% -5.43% -23.86% 29.70% -165.35% -68.82% -56.98% -33.31% -32.59%
NOPAT Growth		 -159.00% -165.11% -31.26% -16.78% -12.56% 26.90% -152.37% -63.49% -65.75% -30.48% -33.57%
Net Income Growth		 -221.00% -45.99% -33.51% -12.35% -20.58% 30.67% -173.54% -58.94% -45.48% -28.48% -47.62%
EPS Growth		 -133.54% -34.55% -16.22% 5.23% 5.52% 47.40% -118.52% -16.38% -32.52% -10.26% -44.85%
Operating Cash Flow Growth		 -6,905.64% -8.09% -46.81% -20.88% 86.42% -920.87% -44.42% -45.36% -49.57% -20.04% -53.88%
Free Cash Flow Firm Growth		 -265.17% 27.00% -50.02% -20.08% 110.81% -1,844.98% -18.13% -56.88% -57.38% -36.13% -28.85%
Invested Capital Growth		 121.16% -110.28% -279.18% -7.32% -3,294.38% 83.33% 69.14% 141.82% -505.63% 117.00% -952.19%
Revenue Q/Q Growth		 -9.58% -61.26% -53.65% -100.00% 95.11% 6.00% -7.12% -28.37% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -49.14% -11.07% -6.28% -2.19% -6.69% -3.59% -19.56% -12.41% -7.24% -9.62% -9.63%
EBIT Q/Q Growth		 -45.64% -10.01% -6.12% -2.47% -6.57% -3.19% -19.41% -12.98% -6.55% -9.93% -9.13%
NOPAT Q/Q Growth		 -39.24% -13.02% -8.63% -1.07% -7.92% -4.42% -17.76% -16.71% -5.09% -9.31% -9.48%
Net Income Q/Q Growth		 -48.73% -9.88% -7.20% -1.45% -7.27% -3.40% -20.17% -10.42% -4.20% -9.81% -12.92%
EPS Q/Q Growth		 -280.33% -15.63% -8.18% 6.32% -5.48% 8.99% -8.59% -5.64% -2.25% -6.36% -12.37%
Operating Cash Flow Q/Q Growth		 -14.53% 2.86% -8.16% -1.18% 85.15% -216.13% -12.27% -16.92% -1.80% -15.81% -10.75%
Free Cash Flow Firm Q/Q Growth		 0.00% 8.98% -6.85% -3.22% 111.86% -199.77% -7.29% -17.43% -5.04% -13.16% -3.24%
Invested Capital Q/Q Growth		 335.94% -34.62% -97.24% 8.20% -629.83% 36.64% -153.79% -22.96% -18.64% 109.09% -200.54%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 0.00% 100.00% 100.00% 100.00% 100.00% 0.00% 0.00% 100.00%
EBITDA Margin		 -97.94% -1,255.52% -10,262.06% 0.00% -608.92% -90.30% -425.49% -1,396.48% 0.00% 0.00% -4,922.39%
Operating Margin		 -60.10% -1,376.43% -10,474.28% 0.00% -627.02% -97.31% -428.45% -1,368.91% 0.00% 0.00% -4,974.27%
EBIT Margin		 -104.60% -1,303.44% -10,474.28% 0.00% -622.89% -92.97% -430.41% -1,420.06% 0.00% 0.00% -4,956.29%
Profit (Net Income) Margin		 -101.12% -1,275.49% -9,872.67% 0.00% -609.09% -89.65% -427.85% -1,328.95% 0.00% 0.00% -4,612.13%
Tax Burden Percent		 100.00% 100.00% 95.66% 99.93% 99.94% 99.12% 99.99% 100.09% 99.84% 98.29% 100.29%
Interest Burden Percent		 96.67% 97.86% 98.54% 100.52% 97.84% 97.29% 99.41% 93.50% 86.87% 85.04% 92.78%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% -1,625.06% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% -1,615.90% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 1,588.25% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -23.54% -36.81% -61.51% -49.55% -42.60% -21.90% -21.87% -19.72% -22.12% -27.85% -51.76%
Cash Return on Invested Capital (CROIC)		 -847.57% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -12,756.74% 0.00% -39,634.18% 0.00%
Operating Return on Assets (OROA)		 -21.53% -35.76% -57.35% 0.00% -31.49% -17.75% -20.85% -20.20% 0.00% 0.00% -51.94%
Return on Assets (ROA)		 -20.81% -34.99% -54.05% 0.00% -30.80% -17.12% -20.73% -18.91% 0.00% 0.00% -48.34%
Return on Common Equity (ROCE)		 -23.54% -36.81% -61.51% -46.80% -39.23% -20.62% -21.40% -19.60% -22.12% -27.85% -51.76%
Return on Equity Simple (ROE_SIMPLE)		 -25.81% -35.99% -85.45% -33.40% -45.22% -16.83% -14.34% -17.38% -19.66% -31.04% 0.00%
Net Operating Profit after Tax (NOPAT)		 -6.55 -17 -23 -27 -30 -22 -55 -90 -150 -196 -261
NOPAT Margin		 -42.07% -963.50% -7,331.99% 0.00% -438.91% -68.12% -299.91% -958.24% 0.00% 0.00% -3,481.99%
Net Nonoperating Expense Percent (NNEP)		 -12.89% -9.16% -15.65% -11.15% -10.10% -4.57% -6.47% -5.50% -3.94% -4.61% -12.65%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - -12.53% -16.15% -25.90% -44.89%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 62.82% 376.71% 2,351.45% 0.00% 158.19% 40.24% 119.15% 347.78% 0.00% 0.00% 1,061.76%
R&D to Revenue		 97.27% 1,099.72% 8,222.83% 0.00% 568.82% 157.07% 409.30% 1,121.13% 0.00% 0.00% 4,012.51%
Operating Expenses to Revenue		 160.10% 1,476.43% 10,574.28% 0.00% 727.02% 197.31% 528.45% 1,468.91% 0.00% 0.00% 5,074.27%
Earnings before Interest and Taxes (EBIT)		 -16 -24 -33 -34 -43 -30 -79 -134 -210 -280 -372
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -15 -23 -32 -33 -42 -29 -78 -132 -208 -277 -369
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 1.89 2.16 1.42 1.67 4.03 3.29 2.97 3.42 3.25 3.96 5.95
Price to Tangible Book Value (P/TBV)		 1.89 2.16 1.42 1.67 4.03 3.29 2.97 3.42 3.25 3.96 5.95
Price to Revenue (P/Rev)		 7.42 76.42 163.49 0.00 49.66 16.74 87.41 261.41 0.00 0.00 461.80
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 23.89 0.00 0.00 0.00 0.00 0.00 0.00 2,397.45 0.00 4,450.58 0.00
Enterprise Value to Revenue (EV/Rev)		 3.66 40.84 44.96 0.00 32.37 11.48 57.91 185.01 0.00 0.00 383.66
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 76.98 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.19 0.15 0.17 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.17 0.15 0.12 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.07 -0.98 -1.01 -1.01 -1.18 -1.15 -1.01 -1.00 -1.00 -1.00 -1.00
Leverage Ratio		 1.13 1.05 1.14 1.21 1.38 1.28 1.06 1.04 1.04 1.05 1.07
Compound Leverage Factor		 1.09 1.03 1.12 1.22 1.35 1.24 1.05 0.98 0.91 0.89 0.99
Debt to Total Capital		 0.00% 0.00% 15.92% 12.69% 14.45% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 1.64% 0.00% 4.32% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 14.28% 12.69% 10.13% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 6.54% 7.19% 4.51% 1.41% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 84.08% 80.77% 78.36% 95.49% 98.59% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 -0.21 -0.45 -0.37 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 1.16 3.12 3.03 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 -0.19 -0.45 -0.26 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 -0.30 -0.56 -0.52 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 1.62 3.92 4.20 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 -0.27 -0.56 -0.36 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 21.66 20.07 -3.53 2.84 1.21 16.76 43.85 44.77 48.12 39.64 36.73
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 5.55% 7.92% 5.87% 2.14% 0.61% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 21.88 18.31 10.98 29.46 3.34 12.30 39.03 26.44 23.65 17.85 13.42
Quick Ratio		 21.20 17.94 10.80 29.00 3.28 12.10 38.72 26.12 23.43 17.66 13.17
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -20 -15 -22 -27 2.87 -50 -59 -93 -146 -199 -256
Operating Cash Flow to CapEx		 -3,285.48% -7,013.26% -9,119.37% -6,848.92% -380.16% -1,824.95% -3,390.34% -3,490.95% -2,690.26% -5,898.83% -34,933.42%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 -19.05 2.00 -34.04 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 -24.91 -3.29 -32.69 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 -25.27 -4.15 -34.48 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.21 0.03 0.01 0.00 0.05 0.19 0.05 0.01 0.00 0.00 0.01
Accounts Receivable Turnover		 58.78 7.00 0.97 0.00 14.17 24.41 8.04 5.03 0.00 0.00 5.28
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 6.98 1.06 0.25 0.00 5.15 12.34 4.60 1.72 0.00 0.00 0.79
Accounts Payable Turnover		 0.00 0.00 0.00 1.60 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 6.21 52.13 374.39 0.00 25.76 14.95 45.40 72.56 0.00 0.00 69.11
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 228.19 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 6.21 52.13 374.39 0.00 25.76 14.95 45.40 72.56 0.00 0.00 69.11
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 2.38 -0.25 -0.93 -1.00 -34 -5.64 -1.74 0.73 -2.95 0.50 -4.28
Invested Capital Turnover		 -3.51 1.69 -0.53 0.00 -0.39 -1.63 -4.99 -18.63 0.00 0.00 -3.97
Increase / (Decrease) in Invested Capital		 14 -2.63 -0.68 -0.07 -33 28 3.90 2.47 -3.68 3.46 -4.78
Enterprise Value (EV)		 57 74 14 63 221 369 1,068 1,745 2,083 2,234 2,877
Market Capitalization		 116 138 51 159 339 538 1,612 2,466 3,014 2,989 3,463
Book Value per Share		 $4.25 $3.57 $2.00 $3.79 $3.26 $4.67 $10.51 $11.54 $14.18 $9.90 $7.53
Tangible Book Value per Share		 $4.25 $3.57 $2.00 $3.79 $3.26 $4.67 $10.51 $11.54 $14.18 $9.90 $7.53
Total Capital		 61 64 43 118 108 171 550 721 928 755 582
Total Debt		 0.00 0.00 6.80 15 16 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 6.10 15 11 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -59 -64 -37 -104 -126 -177 -552 -721 -931 -754 -586
Capital Expenditures (CapEx)		 0.55 0.28 0.32 0.51 1.24 2.64 2.05 2.89 5.62 3.08 0.80
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -0.57 -2.06 -2.23 -2.09 -35 -10.00 -7.08 -14 -20 -27 -30
Debt-free Net Working Capital (DFNWC)		 58 62 41 117 106 167 545 578 618 600 519
Net Working Capital (NWC)		 58 62 41 117 101 167 545 578 618 600 519
Net Nonoperating Expense (NNE)		 9.20 5.63 7.90 7.87 12 6.93 24 35 33 39 85
Net Nonoperating Obligations (NNO)		 -59 -64 -37 -104 -126 -177 -552 -721 -931 -754 -586
Total Depreciation and Amortization (D&A)		 1.04 0.86 0.66 0.87 0.95 0.86 0.91 2.22 2.06 3.81 2.54
Debt-free, Cash-free Net Working Capital to Revenue		 -3.64% -114.09% -716.72% 0.00% -515.76% -31.07% -38.38% -153.60% 0.00% 0.00% -400.39%
Debt-free Net Working Capital to Revenue		 372.88% 3,443.65% 13,324.12% 0.00% 1,554.21% 519.19% 2,954.37% 6,122.49% 0.00% 0.00% 6,918.09%
Net Working Capital to Revenue		 372.88% 3,443.65% 13,099.04% 0.00% 1,486.12% 519.19% 2,954.37% 6,122.49% 0.00% 0.00% 6,918.09%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($1.10) ($1.48) ($1.71) ($1.63) ($1.54) ($0.81) ($1.77) ($2.06) ($2.73) ($3.01) ($4.36)
Adjusted Weighted Average Basic Shares Outstanding		 14.28M 15.49M 17.99M 19.43M 34.96M 35.81M 51.92M 60.54M 66.89M 77.89M 79.25M
Adjusted Diluted Earnings per Share		 ($1.10) ($1.48) ($1.72) ($1.63) ($1.54) ($0.81) ($1.77) ($2.06) ($2.73) ($3.01) ($4.36)
Adjusted Weighted Average Diluted Shares Outstanding		 14.28M 15.49M 18.00M 19.43M 34.96M 35.81M 51.92M 60.54M 66.89M 77.89M 79.25M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($1.48) ($1.71) ($1.63) ($1.54) ($0.81) ($1.77) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 14.40M 17.94M 18.00M 25.75M 25.94M 34.54M 43.63M 63.04M 75.43M 76.54M 83.19M
Normalized Net Operating Profit after Tax (NOPAT)		 -6.55 -17 -23 -27 -30 -22 -55 -90 -150 -196 -261
Normalized NOPAT Margin		 -42.07% -963.50% -7,331.99% 0.00% -438.91% -68.12% -299.91% -958.24% 0.00% 0.00% -3,481.99%
Pre Tax Income Margin		 -101.12% -1,275.49% -10,320.90% 0.00% -609.43% -90.45% -427.88% -1,327.70% 0.00% 0.00% -4,598.59%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 -24.64 -29.66 -20.32 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 -19.10 -20.90 -14.89 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 -25.00 -30.53 -22.11 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 -19.47 -21.77 -16.68 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Xenon Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Xenon Pharmaceuticals' official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 - - - - - - - - - - 83,190,316.00
DEI Adjusted Shares Outstanding		 - - - - - - - - - - 83,190,316.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - - - - -1.25
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 -100.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -100.00%
EBITDA Growth		 -33.19% -34.25% -25.31% -27.67% -35.09% -40.43% -23.60% -34.25% -31.62% -39.81% -54.34%
EBIT Growth		 -36.27% -31.73% -25.64% -27.47% -32.08% -47.20% -23.49% -33.92% -31.30% -39.40% -53.75%
NOPAT Growth		 -46.04% -23.92% -20.37% -24.23% -32.31% -44.29% -23.20% -36.36% -30.76% -41.68% -54.43%
Net Income Growth		 -30.45% -19.65% -14.87% -22.05% -29.57% -46.81% -35.71% -46.24% -44.76% -60.25% -57.27%
EPS Growth		 -28.07% -10.17% 1.59% -4.17% -10.96% -27.69% -33.87% -42.67% -41.98% -57.83% -40.96%
Operating Cash Flow Growth		 -58.14% -0.20% -25.48% 1.63% -6.38% -53.63% -33.48% -106.19% -44.47% -49.82% -44.19%
Free Cash Flow Firm Growth		 -25.51% -3.37% -46.22% -33.41% -36.55% -70.15% -39.89% -71.68% -59.08% -24.91% -4.08%
Invested Capital Growth		 -363.39% -505.63% 720.88% -14.21% -121.98% 117.00% 467.70% 239.48% 177.01% -952.19% -114.05%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -100.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -0.49% -0.74% -10.39% -17.43% -6.33% -4.73% 5.47% -27.56% -4.23% -14.27% -1.59%
EBIT Q/Q Growth		 -2.58% 3.53% -9.76% -17.36% -6.29% -7.51% 7.92% -27.27% -4.21% -14.14% -1.56%
NOPAT Q/Q Growth		 -0.11% 3.57% -9.96% -17.04% -6.62% -5.16% 6.12% -29.55% -2.24% -13.94% -2.33%
Net Income Q/Q Growth		 -2.11% 7.67% -7.13% -20.85% -8.40% -4.61% 0.97% -30.22% -7.31% -15.80% 2.81%
EPS Q/Q Growth		 -1.39% 10.96% 4.62% -20.97% -8.00% -2.47% 0.00% -28.92% -7.48% -13.91% 10.69%
Operating Cash Flow Q/Q Growth		 -44.72% 26.37% -21.75% 24.32% -56.51% -6.33% -13.36% -4.19% -11.71% -13.56% -9.10%
Free Cash Flow Firm Q/Q Growth		 0.29% 4.61% -29.63% -8.20% -2.06% -18.86% -6.58% -32.79% 5.43% 6.68% 11.18%
Invested Capital Q/Q Growth		 56.60% -18.64% 176.53% -389.82% 15.65% 109.09% 2,455.78% -28.79% -53.43% -200.54% 57.88%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 100.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -960.59% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -969.84% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -969.37% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -867.29% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 99.68% 99.54% 100.87% 99.43% 99.49% 94.47% 100.66% 99.27% 100.75% 100.51% 97.55%
Interest Burden Percent		 87.44% 83.80% 80.71% 84.32% 85.94% 88.07% 88.88% 92.22% 93.56% 95.15% 93.82%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -674.84% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -673.05% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 666.67% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -25.19% -22.12% -23.95% -26.71% -29.75% -27.85% -8.17% 0.00% -45.14% -51.76% -37.53%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% -7,055.52% 0.00% 0.00% -39,634.18% -2,858.40% -2,609.13% -5,836.10% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -8.75% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -7.83% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -25.19% -22.12% -23.95% -26.71% -29.75% -27.85% -8.17% 0.00% -45.14% -51.76% -37.53%
Return on Equity Simple (ROE_SIMPLE)		 -27.50% 0.00% -21.25% -23.58% -26.75% 0.00% -35.72% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -39 -38 -41 -48 -52 -54 -51 -66 -67 -77 -79
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -678.89% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -1.36% -0.87% -0.84% -1.27% -1.56% -1.36% -1.79% -2.54% -3.45% -4.24% -2.33%
Return On Investment Capital (ROIC_SIMPLE)		 - -4.05% - - - -7.18% -7.23% -10.40% -12.05% -13.21% -5.88%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 253.84% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 816.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 1,069.84% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -56 -54 -59 -69 -73 -79 -73 -93 -96 -110 -112
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -54 -54 -58 -68 -73 -76 -72 -92 -96 -109 -111
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 3.44 3.25 3.66 3.49 3.74 3.96 3.65 3.79 5.53 5.95 3.62
Price to Tangible Book Value (P/TBV)		 3.44 3.25 3.66 3.49 3.74 3.96 3.65 3.79 5.53 5.95 3.62
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 342.40 320.23 412.77 461.80 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 1,045.10 0.00 0.00 4,450.58 146.29 194.50 597.07 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 250.25 236.92 338.74 383.66 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.00 -1.00 -1.00 -1.01 -1.01 -1.00 -0.99 -1.00 -1.00 -1.00 -0.99
Leverage Ratio		 1.04 1.04 1.04 1.05 1.05 1.05 1.04 1.05 1.06 1.07 1.04
Compound Leverage Factor		 0.91 0.87 0.84 0.89 0.90 0.92 0.93 0.97 1.00 1.02 0.98
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 37.44 48.65 61.80 43.64 46.20 40.47 37.92 33.97 36.17 38.10 58.54
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 21.46 23.65 31.82 23.27 22.21 17.85 17.66 15.14 12.52 13.42 27.79
Quick Ratio		 21.32 23.43 31.52 23.09 22.06 17.66 17.43 14.79 12.08 13.17 27.53
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -36 -34 -44 -48 -49 -58 -61 -82 -77 -72 -64
Operating Cash Flow to CapEx		 -4,006.58% -45,385.90% -22,967.02% -2,158.45% -8,668.98% -6,945.72% -143,376.74% -40,912.74% -25,534.52% -25,622.96% -66,839.85%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.01 0.01 0.01 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 1.58 7.69 8.57 5.28 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.79 0.78 0.79 0.79 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 230.73 47.45 42.58 69.11 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 230.73 47.45 42.58 69.11 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -2.49 -2.95 2.26 -6.55 -5.53 0.50 13 9.14 4.26 -4.28 -1.80
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.99 5.80 -11.81 -3.97 0.00
Increase / (Decrease) in Invested Capital		 -3.43 -3.68 2.62 -0.82 -3.04 3.46 11 16 9.78 -4.78 -15
Enterprise Value (EV)		 1,552 2,083 2,362 2,092 2,180 2,234 1,877 1,777 2,541 2,877 3,498
Market Capitalization		 2,191 3,014 3,247 2,943 2,983 2,989 2,568 2,402 3,096 3,463 4,838
Book Value per Share		 $9.92 $14.18 $11.77 $11.18 $10.53 $9.90 $9.20 $8.26 $7.26 $7.53 $16.08
Tangible Book Value per Share		 $9.92 $14.18 $11.77 $11.18 $10.53 $9.90 $9.20 $8.26 $7.26 $7.53 $16.08
Total Capital		 637 928 888 844 798 755 704 634 560 582 1,338
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -639 -931 -885 -851 -803 -754 -691 -625 -555 -586 -1,340
Capital Expenditures (CapEx)		 1.20 0.08 0.19 1.51 0.59 0.78 0.04 0.16 0.28 0.32 0.13
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -20 -20 -15 -25 -24 -27 -16 -20 -20 -30 -28
Debt-free Net Working Capital (DFNWC)		 506 618 685 697 630 600 534 467 442 519 1,067
Net Working Capital (NWC)		 506 618 685 697 630 600 534 467 442 519 1,067
Net Nonoperating Expense (NNE)		 9.48 7.16 6.60 9.55 11 11 14 19 23 28 24
Net Nonoperating Obligations (NNO)		 -639 -931 -885 -851 -803 -754 -691 -625 -555 -586 -1,340
Total Depreciation and Amortization (D&A)		 1.73 -0.63 0.60 0.66 0.67 2.75 0.66 0.63 0.64 0.61 0.59
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -214.96% -271.20% -272.88% -400.39% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 7,113.43% 6,229.40% 5,890.69% 6,918.09% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 7,113.43% 6,229.40% 5,890.69% 6,918.09% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.73) ($0.65) ($0.62) ($0.75) ($0.81) ($0.83) ($0.83) ($1.07) ($1.15) ($1.31) ($1.17)
Adjusted Weighted Average Basic Shares Outstanding		 66.00M 66.89M 77.59M 77.67M 77.93M 77.89M 78.69M 78.95M 79.25M 79.25M 87.35M
Adjusted Diluted Earnings per Share		 ($0.73) ($0.65) ($0.62) ($0.75) ($0.81) ($0.83) ($0.83) ($1.07) ($1.15) ($1.31) ($1.17)
Adjusted Weighted Average Diluted Shares Outstanding		 66.00M 66.89M 77.59M 77.67M 77.93M 77.89M 78.69M 78.95M 79.25M 79.25M 87.35M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 65.43M 75.43M 75.47M 75.76M 76.24M 76.54M 76.73M 77.11M 77.28M 83.19M 96.67M
Normalized Net Operating Profit after Tax (NOPAT)		 -39 -38 -41 -48 -52 -54 -51 -66 -67 -77 -79
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -678.89% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -861.60% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Here’s a concise trend snapshot for Xenon Pharmaceuticals (XENE) using the last four years of quarterly statements. The company shows ongoing operating losses, essentially no revenue in recent periods, and a cash profile that has been supported largely by investing and financing activities rather than operations.

  • Q4 2025: Financing activities generated strong liquidity, with net cash from financing activities of $113,537,000.
  • Q4 2025: Investing activities produced a meaningful cash inflow, including $123,915,000 from sale/maturity of investments, contributing to a net cash from continuing investing activities of $62,697,000.
  • Q4 2025: Net change in cash and equivalents was a positive $94,649,000, supported by financing and investing inflows.
  • No debt on the balance sheet in recent quarters; total liabilities were around $48.3 million while total equity was about $559.5 million (Q3 2025), indicating a strong equity cushion relative to liabilities.
  • Revenue remains essentially zero across recent quarters (e.g., Q3 2025 shows Operating Revenue and Total Revenue at 0), highlighting that Xenon is still in a pre-revenue development phase.
  • R&D and SG&A continue to drive costs, with 2025 Q4 total operating expenses at $109.767 million (SG&A $22.068 million; RD $87.699 million), indicating substantial burn relative to revenue.
  • Total assets have fluctuated in the mid-to-high hundreds of millions in 2025 (e.g., around $0.6B–$0.74B across the period), reflecting ongoing asset growth and adjustments as the company funds operations.
  • Net income attributable to common shareholders was negative in every 2025 quarter, including Q4 2025 at −$105.403 million and Q3 2025 at −$90.532 million, signaling continued large losses per period.
  • Operating cash flow was negative in all 2025 quarters (Q4 2025: −$81.481 million; Q3 2025: −$71.752 million; Q2 2025: −$64.233 million; Q1 2025: −$61.652 million), highlighting sustained cash burn from operations.
  • Retained earnings deficit remains substantial (approximately −$1.14 billion by early 2025), underscoring a long-running equity-funded burn and insufficient cumulative profits to date.
05/25/26 09:29 PM ETAI Generated. May Contain Errors.

Xenon Pharmaceuticals Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Xenon Pharmaceuticals' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Xenon Pharmaceuticals' net income appears to be on an upward trend, with a most recent value of -$345.91 million in 2025, rising from -$15.75 million in 2015. The previous period was -$234.33 million in 2024. View Xenon Pharmaceuticals' forecast to see where analysts expect Xenon Pharmaceuticals to go next.

Xenon Pharmaceuticals' total operating income in 2025 was -$373.07 million, based on the following breakdown:
  • Total Gross Profit: $7.50 million
  • Total Operating Expenses: $380.57 million

Over the last 10 years, Xenon Pharmaceuticals' total revenue changed from $15.58 million in 2015 to $7.50 million in 2025, a change of -51.9%.

Xenon Pharmaceuticals' total liabilities were at $51.40 million at the end of 2025, a 18.9% increase from 2024, and a 1,663.4% increase since 2015.

In the past 10 years, Xenon Pharmaceuticals' cash and equivalents has ranged from $17.10 million in 2016 to $199.16 million in 2025, and is currently $199.16 million as of their latest financial filing in 2025.

Over the last 10 years, Xenon Pharmaceuticals' book value per share changed from 4.25 in 2015 to 7.53 in 2025, a change of 77.3%.


Related Companies

Financial statements for NASDAQ:XENE last updated on 5/8/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...
Brownstone Research | Sponsoredtc pixel
$30 stock to buy before Starlink goes public (WATCH NOW!)
In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...
Paradigm Press | Sponsoredtc pixel
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
SpaceX IPO hides a much bigger story
The SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...
Weiss Ratings | Sponsoredtc pixel
SpaceX will mint billionaires. You won't be one of them.
By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...
Behind the Markets | Sponsoredtc pixel
Satellite Images Spot Potential $10 Trillion Discovery
'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...
Altimetry | Sponsoredtc pixel
Hey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...
After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...
Banyan Hill Publishing | Sponsoredtc pixel